公开(公告)号：US20240046473A1

公开(公告)日：2024-02-08

申请号：US18482697

申请日：2023-10-06

Applicant: Ventana Medical Systems, Inc. ,  Genentech, Inc.

Inventor： Xingwei WANG ,  Auranuch LORSAKUL ,  Zuo ZHAO ,  Yao NIE ,  Hartmut KOEPPEN ,  Hauke KOLSTER ,  Kandavel SHANMUGAM

IPC: G06T7/00 ,  G16H30/40

CPC classification number: G06T7/0012 ,  G16H30/40 ,  G06T2207/20084 ,  G06T2207/20081

Abstract: The present disclosure relates to techniques for obtaining a synthetic immunohistochemistry (IHC) image from a histochemically stained image. Particularly, aspects of the present disclosure are directed to accessing an input image that depicts a tissue section that has been stained with at least one histochemical stain; generating a synthetic image by processing the input image using a trained generator network; and outputting the synthetic image. The synthetic image depicts a tissue section that has been stained with at least one IHC stain that targets a first antigen, and techniques may also include receiving an input that is based on a level of expression of a first antigen from the synthetic image and/or generating, from the synthetic image, a value that is based on a level of expression of the first antigen.

公开(公告)号：US20240046303A1

公开(公告)日：2024-02-08

申请号：US18451452

申请日：2023-08-17

Applicant: Genentech, Inc.

Inventor： Gordon Bray ,  Iris Chan

IPC: G06Q30/0241 ,  A61K31/437 ,  C12Q1/6886 ,  A61K31/4523

CPC classification number: G06Q30/0241 ,  A61K31/437 ,  C12Q1/6886 ,  A61K31/4523 ,  C12Q2600/106

Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer.

公开(公告)号：US20240033351A1

公开(公告)日：2024-02-01

申请号：US18045313

申请日：2022-10-10

Applicant: Genentech, Inc.

Inventor： Paul BRUNETTA

IPC: A61K39/395 ,  C07K16/28 ,  A61K31/138 ,  A61K31/167 ,  A61K31/5377 ,  A61K31/573 ,  A61K45/06

CPC classification number: A61K39/3955 ,  C07K16/2887 ,  A61K31/138 ,  A61K31/167 ,  A61K31/5377 ,  A61K31/573 ,  A61K45/06 ,  C07K2317/71 ,  C07K2317/24 ,  C07K2317/77 ,  C07K2317/41 ,  C07K2317/73 ,  C07K2317/734 ,  C07K2317/524 ,  C07K2317/70 ,  A61K2039/507

Abstract: The invention provides methods for treating or delaying progression of lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. The invention also provides methods for treating or delaying progression of rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) in an individual. In some embodiments, the methods comprise administering an effective amount of an anti-CD20 antibody.

公开(公告)号：US20240025919A1

公开(公告)日：2024-01-25

申请号：US18199449

申请日：2023-05-19

Applicant: Genentech, Inc.

Inventor： Matthew Leo Landry ,  Christian Nilewski ,  Michael Siu ,  Elisia Villemure ,  Yong Wang ,  BinQing Wei ,  Melissa Ann Ashley ,  Steven Do ,  Lewis John Gazzard ,  Samantha Alyson Green

IPC: C07D519/00 ,  C07D498/22 ,  A61P35/00

CPC classification number: C07D519/00 ,  A61P35/00 ,  C07D498/22

Abstract: Provided herein are aza-tetracyclic oxazepinyl compounds useful in the treatment of cancers.

公开(公告)号：US11881286B2

公开(公告)日：2024-01-23

申请号：US17033161

申请日：2020-09-25

Applicant: GENENTECH, INC.

Inventor： Akshata Ramrao Udyavar ,  Yulei Wang ,  Cleopatra Kozlowski

IPC: G16B40/00 ,  A61P35/00 ,  C07K16/22 ,  C07K16/28 ,  A61K39/00 ,  A61K38/21

CPC classification number: G16B40/00 ,  A61K38/217 ,  A61P35/00 ,  C07K16/22 ,  C07K16/2827 ,  A61K2039/507 ,  C07K2317/76

Abstract: A machine-learning model (e.g., a clustering model) may be used to predict a phenotype of a tumor based on expression levels of a set of genes. The set of genes may have been identified using a same or different machine-learning model. The phenotype may include an immune-excluded, immune-desert or an inflamed/infiltrated phenotype. A treatment strategy and/or treatment recommendation may be identified based on the predicted phenotype.

公开(公告)号：USD1009935S1

公开(公告)日：2024-01-02

申请号：US29733515

申请日：2020-05-04

Applicant: GENENTECH, INC.

Designer： Philip Thepkaysone

Abstract: FIG. 1 is a front view of a display screen or portion thereof with graphical user interface showing the claimed design;
FIG. 2 is a front view of a display screen or portion thereof with graphical user interface showing an alternative embodiment of the claimed design;
FIG. 3 is a front view of a display screen or portion thereof with graphical user interface showing an alternative embodiment of the claimed design; and,
FIG. 4 is a front view of a display screen portion with the graphical user interface of FIG. 1, in which a mobile terminal in broken lines is provided to illustrate an example environment.
The broken lines in the figures show a display screen or portion thereof and a mobile terminal, which form no part of the claimed design. The difference in shading in FIGS. 1, 2, and 3 indicate a contrast of appearance and does not depict any particular color, texture or material.

公开(公告)号：US20230416825A1

公开(公告)日：2023-12-28

申请号：US18192505

申请日：2023-03-29

Applicant: Genentech, Inc.

Inventor： Amy Dressen ,  David B. Iaea ,  Moulay Hicham Alaoui Ismaili ,  Janet K. Jackman ,  Robert A. Lazarus ,  Kelly Michele Loyet ,  Henry R. Maun ,  Brian Louis Yaspan ,  Tangsheng Yi ,  Joseph R. Arron ,  Hilda Y Hernandez-Barry

IPC: C12Q1/6883 ,  C07K16/40 ,  C07K14/81 ,  G01N33/68 ,  C12N9/64

CPC classification number: C12Q1/6883 ,  C07K16/40 ,  C07K14/8135 ,  G01N33/6893 ,  C12N9/6445 ,  C12Q2600/106 ,  C12Q2600/156 ,  A61K38/00

Abstract: Provided herein are methods of treating a subject, methods of predicting the response of a subject and selecting a subject suffering from a disease associated with KLK5, such as asthma or Netherton Syndrome. In particular, provided herein are uses of KLK5 antagonists for the treatment or diagnosis of asthma or Netherton Sydrome, such as an antibody or an Fc fusion polypeptide as well as pharmaceutical formulations comprising the same.

公开(公告)号：US20230416401A1

公开(公告)日：2023-12-28

申请号：US18166994

申请日：2023-02-09

Applicant: Genentech, Inc.

Inventor： Reed J. HARRIS ,  Paul MOTCHNIK

IPC: C07K16/32 ,  C07K16/06 ,  C07K1/18 ,  C07K16/28

CPC classification number: C07K16/32 ,  C07K16/065 ,  C07K1/18 ,  G01N27/447 ,  C07K16/2863 ,  C07K2317/41 ,  C07K16/2896

Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.

公开(公告)号：US20230414750A1

公开(公告)日：2023-12-28

申请号：US18188168

申请日：2023-03-22

Applicant: Hoffmann-La Roche Inc. ,  Genentech, Inc.

Inventor： Maria FILIPPOU-FRYE ,  Joseph Nathaniel PAULSON ,  Leonardo ROQUE PEREIRA ,  Emily PICCIONE GRIFFIN ,  Stephen James SIMKO, III ,  Johanna SY ,  Akiko TAGAWA ,  Beate WULFF ,  Betsy Lane ALTHAUS ,  David CARLILE ,  Nassim DJEBLI

IPC: A61K39/395 ,  A61P35/00 ,  A61K31/664 ,  A61K31/282 ,  A61K31/7048 ,  A61K38/19 ,  A61K31/185 ,  A61K31/573 ,  A61K31/138 ,  A61K31/167 ,  C07K16/28

CPC classification number: A61K39/3955 ,  A61P35/00 ,  A61K31/664 ,  A61K31/282 ,  A61K31/7048 ,  A61K38/193 ,  A61K2039/545 ,  A61K31/573 ,  A61K31/138 ,  A61K31/167 ,  C07K16/2887 ,  C07K16/2809 ,  A61K31/185

Abstract: The present invention relates to methods of treating B-cell proliferative disorders, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering an anti-CD20/anti-CD3 bispecific antibody and in combination with an anti-CD20 antibody (e.g., obinutuzumab or rituximab) and one or more chemotherapeutic agents selected from ifosfamide, carboplatin, and/or etoposide.

公开(公告)号：US20230408416A1

公开(公告)日：2023-12-21

申请号：US18140891

申请日：2023-04-28

Applicant: GENENTECH, INC.

Inventor： Aron Lee ,  Rashmi Sharma ,  Justin Joo-Ho Jeong ,  Michael Tae-Jon Kim

IPC: G01N21/77

CPC classification number: G01N21/77 ,  G01N2021/7786

Abstract: The present disclosure relates to methods and kits for detecting a free thiol in a substrate as well as methods for quantifying the amount of free thiol in a substrate. In particular, the present disclosure provides a fluorescent Ellman assay for enhanced sensitivity of free thiol detection and quantification.